Tuesday, June 12, 2018 9:57:29 PM
The main thing that I am not seeming to understand with this deal is what is keeping these large investors from buying up as much shares as they can up to the day of record squeezing this sky high then shorting the crap out of it and dump all there shares. Then the would have no shares long but still a "holder of record" and would be able to risk free cover short position @1.75 with rights offering shares? And after short position covered buy up long position as well @1.75 through offering. They would be getting paid to bring there cost basis down to 1.75. At least that's what I would do if I were them. Is there anything that would stop them from doing this? I feel Ike this is just to obvious and easy to be possible. But don't see why not?
Recent DCTH News
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
- Delcath Systems Reports Fourth Quarter and Full Year 2025 Results • Business Wire • 02/26/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:05 AM
- Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call • Business Wire • 02/12/2026 01:00:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/10/2026 07:41:34 PM
- Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference • Business Wire • 01/27/2026 01:05:00 PM
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/21/2026 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 09:41:41 PM
- Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results • Business Wire • 01/09/2026 01:05:00 PM
- Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma • Business Wire • 12/31/2025 01:00:00 PM
